All In Biotech

Drug Trial Radar · NCT03997370

Evaluation of Dosing Procedures of Chemotherapy Treatment (Carboplatin) With the Contrast Agent Iohexol

Assessment of Carboplatin Clearance Predictors: A PK Study on NCI-Sponsored Clinical Trials or Standard of Care Treatments Using Carboplatin

Last checked: Nov 20, 2026Latest source record: Nov 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

350

Planned (sponsor's estimate)

Start

Jan 15, 2020

Primary completion

Mar 14, 2028

Study completion Mar 14, 2028

Sponsor

Lead sponsor
NRG OncologyAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
National Cancer Institute (NCI)
First posted
Jun 25, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Male only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This trial studies how well iohexol works in helping doctors calculate the dose of carboplatin given to patients with cancer. Drugs used in chemotherapy, such as carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Understanding how to best calculate the dose of carboplatin given to patients with cancer may help doctors learn how to improve the use of carboplatin in the future.

Conditions

  • Malignant Solid Neoplasm

Interventions

  • Biospecimen CollectionProcedure

    Undergo collection of blood samples

  • CarboplatinDrug

    Given IV

  • IohexolDrug

    Given IV

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Accuracy of achieving the targeted carboplatin area under the curve (AUC)Time frame: Up to 4 weeks
  2. Precision of achieving the targeted carboplatin AUCTime frame: Up to 4 weeks
  3. Bias of the formula for estimated glomerular filtration rate (eGFR) currently in existence in patients with cancerTime frame: Up to 4 weeks
  4. Precision of the formula for eGFR currently in existence in patients with cancerTime frame: Up to 4 weeks
  5. Correlation between carboplatin clearance (CL) and mGFRTime frame: Up to 4 weeks

Locations

189 sites in 2 countries. Site status is shown where the registry gives one.

  • University of Arizona Cancer Center-Orange Grove Campus

    Tucson, Arizona

  • Banner University Medical Center - Tucson

    Tucson, Arizona

  • University of Arizona Cancer Center-North Campus

    Tucson, Arizona

  • Mercy Hospital Fort Smith

    Fort Smith, Arkansas

  • CARTI Cancer Center

    Little Rock, Arkansas

  • University of Arkansas for Medical Sciences

    Little Rock, Arkansas

  • UC San Diego Health System - Encinitas

    Encinitas, California

  • UC San Diego Moores Cancer Center

    La Jolla, California

  • University of California Davis Comprehensive Cancer Center

    Sacramento, California

  • UC San Diego Medical Center - Hillcrest

    San Diego, California

  • UCHealth University of Colorado Hospital

    Aurora, Colorado

  • Poudre Valley Hospital

    Fort Collins, Colorado

  • Cancer Care and Hematology-Fort Collins

    Fort Collins, Colorado

  • UCHealth Greeley Hospital

    Greeley, Colorado

  • Medical Center of the Rockies

    Loveland, Colorado

  • Hartford Hospital

    Hartford, Connecticut

  • The Hospital of Central Connecticut

    New Britain, Connecticut

  • Sibley Memorial Hospital

    Washington D.C., District of Columbia

  • Emory University Hospital Midtown

    Atlanta, Georgia

  • Emory University Hospital/Winship Cancer Institute

    Atlanta, Georgia

  • Lewis Cancer and Research Pavilion at Saint Joseph's/Candler

    Savannah, Georgia

  • Saint Alphonsus Cancer Care Center-Boise

    Boise, Idaho

  • Saint Alphonsus Cancer Care Center-Caldwell

    Caldwell, Idaho

  • Kootenai Health - Coeur d'Alene

    Coeur d'Alene, Idaho

  • Walter Knox Memorial Hospital

    Emmett, Idaho

  • Idaho Urologic Institute-Meridian

    Meridian, Idaho

  • Saint Alphonsus Cancer Care Center-Nampa

    Nampa, Idaho

  • Kootenai Clinic Cancer Services - Post Falls

    Post Falls, Idaho

  • Kootenai Clinic Cancer Services - Sandpoint

    Sandpoint, Idaho

  • OSF Saint Anthony's Health Center

    Alton, Illinois

  • Saint Mary's Hospital

    Centralia, Illinois

  • Northwestern University

    Chicago, Illinois

  • University of Chicago Comprehensive Cancer Center

    Chicago, Illinois

  • Carle at The Riverfront

    Danville, Illinois

  • Carle Physician Group-Effingham

    Effingham, Illinois

  • NorthShore University HealthSystem-Evanston Hospital

    Evanston, Illinois

  • NorthShore University HealthSystem-Glenbrook Hospital

    Glenview, Illinois

  • NorthShore University HealthSystem-Highland Park Hospital

    Highland Park, Illinois

  • Northwestern Medicine Lake Forest Hospital

    Lake Forest, Illinois

  • Carle Physician Group-Mattoon/Charleston

    Mattoon, Illinois

Showing 40 of 189 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.